For research and education only · Not reviewed by a medical professional · Disclaimer

Peptide encyclopedia/ IGF-1 DES
Illustration for IGF-1 DES

THE PEPSRADAR ENCYCLOPEDIA

IGF-1 DES

IGF signaling in laboratory tissue models

Research topics · Sources checked 2026-10-04

Read the studies ↓

IGF-1 DES · KEY FACTS

Content updated · how dates work

Saved peptides

What is IGF-1 DES?

Des(1-3) IGF-1 is an IGF-1 analogue missing its first three amino acids. The featured study examined developing rat neural tissue in culture, rather than athletic performance.

Biological role or research focus

IGF signaling in laboratory tissue models.

These tissue-culture findings do not demonstrate muscle growth, strength, or safe use in people.

Role reference: Des (1-3) IGF-I potently enhances differentiated cell growth in olfactory bulb organ culture. · 1994 ↗

Names you may encounter

Des(1-3) IGF-1 · DES IGF-1

Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.

Class / identity
IGF-1 analogue lacking its first three amino acids
Research focus
IGF signaling in laboratory tissue models
Featured evidence
Animal tissue study
Source check
October 4, 2026

Source: Des (1-3) IGF-I potently enhances differentiated cell growth in olfactory bulb organ culture. · 1994 ↗

Quick answers

Is IGF-1 DES FDA approved?
No. No FDA-approved drug contains IGF-1 DES. Source ↗
Is IGF-1 DES safe?
IGF-1 DES is an unapproved IGF-1 analogue with no human safety studies. As a growth factor, its effects on blood sugar and tissue growth in people are unknown. Human safety data: none. The Risks & interactions section below lists what is known. Read the risks ↓
Is IGF-1 DES banned in sport?
Very likely. The 2026 World Anti-Doping Agency (WADA) Prohibited List does not name it, but it appears to fall under a banned class (S2.3 Growth factors and growth factor modulators). Source ↗

What does the evidence show?

Evidence map

Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.

1 Animal / mixed laboratory research
StudyTypePopulation / model
Des(1-3) IGF-1 in olfactory-bulb cultures (1994)Animal tissue studyOlfactory-bulb organ cultures from newborn rats.

Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.

Animal tissue study · 1994

Des(1-3) IGF-1 in olfactory-bulb cultures

What did this publication test, and what did it find?

Population / model
Olfactory-bulb organ cultures from newborn rats.
Study design
Laboratory evaluation of des(1-3) IGF-1 and other growth-factor conditions using cellular and neuronal-marker measures.
Main finding
The publication reported changes in cellular uptake, morphology, and neuronal markers, with stronger activity for the DES analogue on selected readouts.
Limits & context
These tissue-culture findings do not demonstrate muscle growth, strength, or safe use in people.

Source: Des (1-3) IGF-I potently enhances differentiated cell growth in olfactory bulb organ culture. · 1994 ↗

Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.

Registered human trials

No study naming IGF-1 DES as an intervention was found on ClinicalTrials.gov when we last checked (November 16, 2026). That means no registered human trial, not proof that none has ever been done elsewhere.

Further reading · 4 additional publication links

Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.

The effects of insulin-like growth factor (IGF)-1, IGF-2, and des-IGF-1 on neuronal loss after hypoxic-ischemic brain injury in adult rats: evidence for a role for IGF binding proteins. ↗
Endocrinology · 1996 Mar · Journal Article, Research Support, Non-U.S. Gov't

Enforced epithelial expression of IGF-1 causes hyperplastic prostate growth while negative selection is requisite for spontaneous metastogenesis. ↗
Oncogene · 2008 May 1 · Comparative Study, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't

IGF-I has a dual effect on insulin release from isolated, perifused adult rat islets of Langerhans. ↗
The Journal of endocrinology · 1997 Apr · Comparative Study, Journal Article, Research Support, Non-U.S. Gov't

A key functional role for the insulin-like growth factor 1 N-terminal pentapeptide. ↗
The Biochemical journal · 1989 May 1 · Journal Article, Research Support, Non-U.S. Gov't
Read available full text ↗

Repeat this PubMed search ↗
Search additional PubMed records ↗

Risks & interactions

IGF-1 DES is an unapproved IGF-1 analogue with no human safety studies. As a growth factor, its effects on blood sugar and tissue growth in people are unknown.

Human safety data: None

No published human studies were found. The approved IGF-1 medicine mecasermin is a different molecule, and its safety profile does not transfer to this analogue.

Unassessed: no human safety data

It isn't approved, so there is no official list of who should avoid it, and no human safety studies have been published. No condition is tagged, but that does not make it safe for anyone. If a condition applies to you, talk to a doctor or pharmacist first.

Who should not use it

There is no official list, because it has never been approved as a medicine. That is not a sign it is safe for anyone: its risks have not been studied enough to know who is most at risk.

Summarized from published studies with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: Des(1-3) IGF-I in olfactory bulb organ culture (1994) ↗ · IGF-1, IGF-2 and des-IGF-1 after brain injury in rats (1996) ↗

Safety & what remains unknown

Growth-factor activity in a culture system cannot determine systemic glucose, tissue-growth, or long-term safety effects.

Source: Des (1-3) IGF-I potently enhances differentiated cell growth in olfactory bulb organ culture. · 1994 ↗

Evidence boundaries

These tissue-culture findings do not demonstrate muscle growth, strength, or safe use in people.

Source: Des (1-3) IGF-I potently enhances differentiated cell growth in olfactory bulb organ culture. · 1994 ↗

Regulatory status

U.S. FDA approval
Not approved
No FDA-approved drug containing this substance found in Drugs@FDA (openFDA data updated 2026-10-07). source
FDA compounding (503A bulk list)
Not on FDA’s compounding lists
Not found on FDA's 503A category 1, 2 or 3 lists (updated May 14, 2026) or the category 2 safety-risk page (updated April 22, 2026). source
World Anti-Doping Agency (2026)
Likely prohibited under a class rule · S2.3 Growth factors and growth factor modulators
Not named, but S2.3 prohibits "IGF-1 and its analogues" (likely covered). source

Other notes

  • The FDA-approved IGF-1 drug is mecasermin (Increlex, BLA 021839), a different molecule from IGF-1 DES. source

Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.

This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.

Research context & identity

This page distinguishes the DES analogue from native IGF-1 and IGF-1 LR3. Findings should follow the exact analogue and tissue setting.

Source: Des (1-3) IGF-I potently enhances differentiated cell growth in olfactory bulb organ culture. · 1994 ↗

New editorial updates

Loading approved updates…

New source discoveries

Links appear automatically. Unreviewed discoveries are not verified medical findings.

Loading recent discoveries…

Explore the latest source feed →

Sources & supplier listings

Listings are grouped by the vendor’s stated identity. Blends and modified derivatives are labeled separately. Inclusion is not a quality assessment or an endorsement.

No verified matching catalog listing yet

We have not added a supplier for this profile. Missing products and coded listings are not filled with guesses.

Biology & proposed mechanism

The experiment compared growth-factor responses and cellular markers in an organ-culture model. Laboratory potency does not establish a superior clinical treatment.

Source: Des (1-3) IGF-I potently enhances differentiated cell growth in olfactory bulb organ culture. · 1994 ↗

Questions worth asking

  • Can laboratory potency be used to promise greater muscle growth?
  • What material, population, and route were actually studied?
  • These tissue-culture findings do not demonstrate muscle growth, strength, or safe use in people.
  • What adverse effects, uncertainty, and conflicts of interest does the original source report?

Frequently asked questions

Can laboratory potency be used to promise greater muscle growth?

No. Potency on one cell or tissue readout is not a clinical performance outcome.

Source: Des (1-3) IGF-I potently enhances differentiated cell growth in olfactory bulb organ culture. · 1994 ↗

Does the publication verify a supplier’s product?

No. The tested material and a commercial listing need separate identity and batch checks. A research-use disclaimer does not establish clinical suitability.

Source: Des (1-3) IGF-I potently enhances differentiated cell growth in olfactory bulb organ culture. · 1994 ↗

References & editorial record

Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.

For research and education only. This page does not provide medical advice, diagnosis, or treatment. Research-only listings are not instructions for human use.

See something wrong on this page? Report a mistake · Corrections